- Home
- USEA vs TPST Comparison
USEA vs TPST Comparison
Compare USEA & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | TPST |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 14.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | USEA | TPST |
|---|---|---|
| Price | $1.88 | $3.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 68.1K | ★ 242.3K |
| Earning Date | 11-11-2025 | 11-05-2025 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,025,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $3.00 |
| 52 Week High | $2.00 | $13.65 |
Technical Indicators
Market Signals| Indicator | USEA | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 64.32 | 25.89 |
| Support Level | $1.81 | $3.04 |
| Resistance Level | $1.76 | $3.23 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 94.37 | 9.02 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of five dry bulk vessels, comprising two Kamsarmax and three Panamax vessels with an aggregate cargo-carrying capacity of approximately 396,297 dwt.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.